The international interlaboratory quality control program for measurement of antiretroviral drugs in plasma: A global proficiency testing program

Therapeutic Drug Monitoring

Volumn 33, Issue 2, 2011, Pages 239-243

  Burger, David ^a   Teulen, Marga ^a   Eerland, Jaco ^b   Harteveld, Anneke ^b   Aarnoutse, Rob ^a   Touw, Daan ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KKGT   (Netherlands)

Author keywords

HIV; proficiency testing; therapeutic drug monitoring

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; INDINAVIR; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; TIPRANAVIR;

ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; QUALITY CONTROL; SCORING SYSTEM; ULTRAVIOLET SPECTROSCOPY;

ANTI-HIV AGENTS; DRUG MONITORING; EUROPE; HEMATOLOGY; HIV PROTEASE INHIBITORS; HUMANS; INTERNATIONALITY; LABORATORIES; LABORATORY PROFICIENCY TESTING; LABORATORY TECHNIQUES AND PROCEDURES; MICROBIAL SENSITIVITY TESTS; NETHERLANDS; PLASMA; QUALITY CONTROL;

EID: 79953216672     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31820fa528     Document Type: Article

References (10)

1. Working Group of the office of AIDS Research Advisory Council (OARAC). Guidelines for the Use of Antiretroviral Agents in HIV-1- Infected Adults and Adolescents, version December 1, 2010. Available at: http://aidsinfo/nih.gov/ contentfiles/AdultandAdolescentGL.pdf. Accessed September 23, 2010.
2. Gazzard BG. British HIVAssociation Guidelines for the treatment of HIV-1- infected adults with antiretroviral therapy 2008. HIV Med. 2008;9:563-608.
3. Aarnoutse RE, Verweij-van Wissen CPWGM, van Ewijk-Beneken Kolmer EWJ, et al. International interlaboratory quality control program for measurement of antiretroviral drugs in plasma. Antimicrob Agents Chemother. 2002;46:884-886. (Pubitemid 34157682)
4. Droste JA, Aarnoutse RE, Koopmans PP, et al. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr. 2003;32:287-291. (Pubitemid 36331700)
5. US Department of Health and Human Services, Center for Drug Evaluation and Research, and Food and Drug Administration. Guidance for Industry. Bioanalytical Method Validation. Available at: www.fda.gov/cder/guidance/index. html. Accessed September 23, 2010.
6. Anonymous. Medicare, Medicaid and CLIA programs; regulations implementing the Clinical Laboratory Improvement Amendments of 1988 (CLIA)-HCFA. Final rule with comment period. Fed Regist. 1992; 57:7002-7186.
7. Jenny RW, Jackson-Tarentino KY. Causes of unsatisfactory performance in proficiency testing. Clin Chem. 2000;46:89-99. (Pubitemid 30090964)
8. Holland DT, Difrancesco R, Stone J, et al. Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories. Antimicrob Agents Chemother. 2004;48:824-831. (Pubitemid 38280331)
9. Holland DT, Difrancesco R, Connor JD, et al. Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoring. Ther Drug Monit. 2006; 28:367-374. (Pubitemid 44314924)
10. Bruggemann RJ, Touw DJ, Aarnoutse RE, et al. International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. Antimicrob Agents Chemother. 2009; 53:303-305.